The China Biotech Threat Is Already Here | John Gutierrez on Capitol Hill, Drug Pricing & FDA
Last week, seven leading life sciences investors went to Washington. They met with the National Security Commission on Emerging Biotechnology, walked the halls of Congress, and shared which roadblocks are preventing them from being a part of the next breakthrough.
John Gutierrez was one of those investors — and the throughline of nearly every room he walked into was China.
Not as a future threat to get ahead of. But as a current competitor that is already having a real impact on how capital decisions are made and exposing just how much American biotech policy is working against itself.
On…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.